Orchestra BioMed has confirmed Temuro’s participation in a $34m series B1 round, a month after the corporate entered into a strategic agreement that had it invest $5m of equity.
US-based biomedical therapy system developer Orchestra BioMed has closed a $34m series B1 round backed by medical device maker Terumo Corporation.
Perceptive Advisors, RTW Investments and Soleus Capital co-led the round, which also featured unnamed existing investors from SternAegis Ventures. Orchestra BioMed is eligible for up to an additional $57m in series B and B1 funding.
Terumo’s investment was first revealed last month, when the corporate supplied $5m in equity funding to Orchestra on top of a $30m upfront…
Thierry Heles
Thierry Heles is editor-at-large of Global University Venturing and Global Corporate Venturing, and host of the Beyond the Breakthrough podcast.
